The MarketWatch News Department was not involved in the creation of this content. Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent ...
Quantum BioPharma has achieved significant progress with its FSD202 program, receiving human ethics review committee (HREC) approval for a Phase 2 clinical trial targeting nociplastic pain in patients ...
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies, today released its analysis of Quantum BioPharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback